Syntis Bio
Syntis Bio develops novel oral therapies with targeted drug delivery technology to enhance bioavailability.
- 7
- Private company
- Boston, MA, USUnited States
Syntis Bio develops novel oral therapies with targeted drug delivery technology to enhance bioavailability.
syntis.bioCrawled Oct 15, 2026
The Syntis team is on mission to provide accessible, effective and sustainable therapeutic solutions for rare genetic diseases and prevalent health conditions like obesity and diabetes.
Dr. Martin D. Madaus is a Syntis board director and an operating executive with the Carlyle Group, a global investment firm. He has more than 30 years of experience in diagnostics and life science tools as a healthcare CEO, board member, investor and strategy consultant.
To unlock the full therapeutic potential of the small intestine.
Revolutionizing oral therapy for obesity, rare diseases, & beyond
Syntis Bio, Inc. operates the website. Its privacy policy describes the information it collects, how it may be used and shared, and users’ choices.
Syntis Bio reports Phase 1/1b trial results showing **oral SYNT-101 produces placebo-adjusted weight loss** in patients with obesity over a 28-day multiple ascending dose study. The findings replicate satiety hormone modulation effects previously observed in single ascending dose trials, mirroring mechanisms seen in bariatric surgery. The data supports SYNT-101’s potential as a non-surgical obesity intervention targeting appetite regulation.
Sep 2026SyntisNews article
Syntis Bio reports that its obesity treatment candidate **SYNT-101** demonstrates positive initial safety results in Phase 1/1b trials. The drug shows no gastrointestinal adverse events, serious adverse events, or participant discontinuations across all tested doses. These findings support the company’s novel approach to obesity treatment.
Jul 2026SyntisNews article
Syntis Bio appoints **Matthew Dallas** as its new **Chief Financial Officer (CFO)**. Dallas joins the clinical-stage biopharmaceutical company, which develops oral therapeutics targeting the small intestine. He brings over **25 years of financial leadership experience** in life sciences to support Syntis Bio’s growth and operations.
Jun 2026SyntisNews article
Syntis Bio begins dosing the first patient in a Phase 1/1b clinical trial of **SYNT-101**, a candidate therapy for obesity. The company also appoints **David Rosenbaum, Ph.D.** as Chief Development Officer to advance its pipeline. SYNT-101 targets metabolic pathways linked to weight regulation, marking a key step in evaluating its safety and efficacy in human trials.
Mar 2026SyntisNews article